Clinical endocrinology
-
Clinical endocrinology · Mar 2006
Multicenter StudyFirst-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
The majority of patients with acromegaly have large tumours and the outcome of conventional management remains poor. ⋯ In both patients with micro- or macroadenoma, primary octreotide-LAR treatment controls hormone excess, induces tumour shrinkage and improves symptoms of acromegaly with limited side effects and can be therefore successfully employed in patients with contraindications for surgery or in those who refuse surgery.